If you have been wondering whether Exact Sciences is still worth buying after its huge run, you are not alone. This breakdown is designed to help you decide if the current price makes sense. The stock ...

Abbott, a Chicago-based pharmaceutical company, is acquiring Madison-based biotechnology company Exact Sciences, which will become a subsidiary of Abbott, in a $21 billion deal, the companies ...

A new demo of Google’s Nano Banana Pro has set social media buzzing, thanks to a viral post showcasing just how precisely the tool can read and recreate handwritten work. The now-popular image shared ...

Abbot Laboratory has announced a deal to acquire Madison-based Exact Sciences for approximately $21 billion. Exact Sciences, known for its Cologuard cancer screening test, was founded in 1995 and ...

Abbott to buy Exact Sciences in $23 billion deal Exact's flagship colorectal cancer test to join Abbott's portfolio Abbott eyes international expansion for Exact's tests Aims for broad reimbursement ...

Posts from this topic will be added to your daily email digest and your homepage feed. is editor-in-chief of The Verge, host of the Decoder podcast, and co-host of The Vergecast. Let’s talk about AI ...

Abbott Laboratories ABT0.26%increase; green up pointing triangle agreed to acquire cancer diagnostics company Exact Sciences EXAS 0.43%increase; green up pointing triangle in a deal valued at about ...

North suburban-based Abbott Laboratories announced a $21 billion deal Thursday morning to acquire Exact Sciences, the maker of Cologuard — its largest acquisition in a decade. The deal will allow ...

The acquisition will allow the diagnostics giant to enter the rapidly growing market for cancer tests Exact Sciences sells Cologuard, the at-home test for colorectal cancer that allows some patients ...

Abbott Laboratories agreed to acquire cancer diagnostics company Exact Sciences in a deal worth about $21 billion. Exact Sciences shareholders will receive $105 a share. The stock rose 18% to $101.29 ...